Arcutis Biotherapeutics Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Plans
On March 11, 2025, Howard G. Welgus, M.D., a member of our Board of Directors, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential sale of up to 96,814 shares of common stock held by Mr. Welgus, the potential exercise and sale of up to 29,538 options, as well as the potential sale of 10,139 shares resulting from RSUs vesting between June 16, 2025 and May 29, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.